{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-023584","form_type":"8-K","ticker":"LTRN","cik":"0001763950","company_name":"Lantern Pharma Inc.","filed_at":"2022-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.219221+00:00","generated_at":"2026-06-26T01:36:00.707728+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Lantern Pharma Q1 net loss $4.1M; cash $65.2M, RADR platform tops 20B data points","bullets":["Cash and marketable securities $65.2M at March 31, 2022 vs $70.7M at Dec 31, 2021; net cash used $5.3M in Q1.","Net loss $4.1M ($0.38/share) vs $2.5M ($0.24) in Q1 2021; R&D expenses rose to $2.7M from $1.3M.","RADR AI platform surpassed 20 billion data points; on track for 25 billion by year-end 2022.","IND for LP-184 targeted for Q3 2022; HARMONIC Phase 2 trial for LP-300 expected to start enrollment summer 2022.","Share repurchase program extended; $3.6M remaining authorized through July 31, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-023584","json":"https://secwatch.observer/filing/0001213900-22-023584.json","markdown":"https://secwatch.observer/filing/0001213900-22-023584.md","text":"https://secwatch.observer/filing/0001213900-22-023584.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1763950/000121390022023584/0001213900-22-023584-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1763950/000121390022023584/ea159290-8k_lantern.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T01:36:00.707728+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}